-
Roche's Kadcyla beats Herceptin breast cancer disease recurrence and death risk
pharmafile
October 19, 2018
Roche has unveiled new data for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) in the treatment of patients with HER2-positive early breast cancer (eBC) who...
-
Roche signs $1 billion deal with cell therapy firm SQZ biotech
pharmafile
October 19, 2018
The Massachusetts-based cell therapy company SQZ Biotech, has announced the expansion of its collaboration with Swiss pharma giant Roche, in a deal that could be worth up to $1 billion.
-
Roche’s Kadcyla shows promise in early breast cancer
pharmatimes
October 19, 2018
Roche has announced that its antibody drug conjugate Kadcyla cut the risk of disease recurrence when given after neoadjuvant treatment and surgery to certain breast cancer patients with residual disease.
-
Use of Roche’s haemophilia A therapy Hemlibra expanded in the US
pharmatimes
October 11, 2018
Roche’s Hemlibra has been approved in the US for routine prophylaxis of bleeding episodes patients with haemophilia A without factor VIII inhibitors.
-
Roche’s Hemlibra secures extended FDA approval for haemophilia A
pharmaceutical-technology
October 09, 2018
Roche has secured approval from the US Food and Drug Administration (FDA) for the use of Hemlibra (emicizumab-kxwh) to treat haemophilia A patients without factor VIII inhibitors.
-
Roche pays €70M upfront for Tusk’s preclinical Treg depleter
fiercebiotech
September 29, 2018
Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T cells (Tregs) in preclinical tests.
-
Roche aims to improve cancer treatments with DNA blood test
pharmaphorum
September 27, 2018
Roche has launched a blood test that can identify 70 of the most commonly mutated genes in solid tumours, as the company seeks to make more medicine more personalised.
-
Latest lung cancer data could open new avenue for Roche’s Tecentriq
pharmaphorum
September 27, 2018
Roche is eyeing a new use for its checkpoint inhibitor immunotherapy Tecentriq after it posted results showing it extended patients’ lives...
-
Roche's Tecentriq+chemo combo shows first-line benefit in small cell lung cancer
pharmafile
September 27, 2018
Roche has unveiled new Phase 3 data for its cancer immunotherapy Tecentriq (atezolizumab) in combination with carboplatin and etoposide chemotherapy as a first-line treatment...
-
Roche to file entrectinib for ROS-1 positive NSCLC
pharmatimes
September 27, 2018
Roche is planning to file its investigational cancer drug entrectinib following positive results from early and mid-stage trials with patients...